from stage 4 high-risk neuroblastoma
Details of the vaccine trial can be found here.
A journal article published in 2014 presenting outcomes of relapsed patients treated with the vaccine at Memorial Sloan Kettering Cancer Center (MSKCC):
Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission
Brian H. Kushner, Irene Y. Cheung, Shakeel Modak, Kim Kramer, Govind Ragupathi and Nai-Kong V. Cheung
Band of Parents, helping to fund MSKCC’s vital work.